Clinical trials recruiting for Pancreatic Adenocarcinoma

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
  NCT05365581 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 46 locations
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
  NCT07488676 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 94 locations
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
  NCT05877599 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
  NCT05624918 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
  NCT05208762 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
  NCT07090499 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 31 locations
• Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
  NCT06789679 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
  NCT06698458 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 120 Years · Sex: All (male and female) · 15 locations
• Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)
  NCT05657743 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer
  NCT06026943 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
  NCT01365169 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07562152 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
  NCT05000294 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
  NCT06483555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
  NCT03740256 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
  NCT06095141 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
  NCT06199895 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
  NCT00830557 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
  NCT06333314 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 44 locations
• Evaluating Novel Therapies in ctDNA Positive GI Cancers
  NCT05482516 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers
  NCT07478523 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Improving Pancreatic Cancer Care by the Use of Computational Science and Technology
  NCT06055010 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
  NCT07619391 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
  NCT06405490 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
  NCT04605913 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Namodenoson Treatment of Advanced Pancreatic Cancer
  NCT06387342 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
  NCT05268692 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
  NCT05059444 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 57 locations
• Pancreatic Cancer Detection Consortium
  NCT06388967 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
  NCT03384238 · Phase: Phase 1, Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
  NCT05245500 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
  NCT06412510 · Phase: Phase 1, Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · 1 location
• Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
  NCT05083247 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma
  NCT06867172 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer
  NCT06250972 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
  NCT06596915 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
  NCT04361708 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
  NCT07126158 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
  NCT07349537 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
  NCT07621718 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
  NCT05985655 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• TCR1188-ABC Cells in KRAS-mutated Cancers
  NCT07594067 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
  NCT04157127 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer
  NCT05752812 · Phase: Not specified · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.
  NCT07493421 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer
  NCT06149689 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Pancreatic Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Pancreatic Adenocarcinoma trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.